logo
Plus   Neg
Share
Email

Allergan: Atogepant Shows Robust Efficacy, Safety In Phase 2b/3 Trial

Allergan plc (AGN) announced positive results from CGP-MD-01, a Phase 2b/3 clinical trial evaluating the efficacy, safety, and tolerability of orally administered atogepant, a highly potent CGRP receptor antagonist in development for the prevention of migraine. The company said all active treatment arms of atogepant met the primary endpoint across all doses and dose regimens, with a statistically significant reduction from baseline in monthly migraine/probable migraine headache days in patients with episodic migraine treated with atogepant compared with placebo for 12 weeks.

In the CGP-MD-01 trial, atogepant was well tolerated. There was no signal of hepatotoxicity with atogepant in the study with daily administration over 12 weeks. The liver safety profile for atogepant was similar when compared to placebo.

Allergan said the company will continue with its phase 3 program for atogepant following discussions with regulatory authorities.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a move likely to further inflame global trade tensions, President Donald Trump has threatened to impose a 20 percent tariff on all cars imported to the U.S. from the European Union. Trump claimed he would impose the new tariffs unless the EU removes tariffs and trade barriers placed on the U.S. The Federal Reserve has determined that the largest U.S. banks are strongly capitalized and would be able to lend to banks as well as households during a severe global economic recession. This is the fourth straight year that all banks have met the Federal Reserve's standards. The first round of results of the supervisory stress tests were released by the central bank on Thursday. The "safety" driver behind the wheel of a self-driving Uber was streaming a television show on her smartphone up until about the time of a fatal crash in March, according to a report from the Tempe Police Department. Uber's self-driving Volvo SUV, which was traveling at under 44 miles per hour, had struck and killed a pedestrian in Arizona on March 18.
Follow RTT